Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04MSM
|
|||
| Former ID |
DIB013444
|
|||
| Drug Name |
Carbamazepine
|
|||
| Synonyms |
Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Epilepsy [ICD-11: 8A60-8A68] | Approved | [1], [2] | |
| Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | NDA filed | [3] | ||
| Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 3 | [4] | ||
| Company |
Lundbeck Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H12N2O
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
|
|||
| InChI |
1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
|
|||
| InChIKey |
FFGPTBGBLSHEPO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 298-46-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9085, 442467, 621391, 855967, 866528, 3154113, 5051955, 7847318, 7978855, 8149231, 8151689, 10321205, 10517602, 11109646, 11110939, 11110940, 11207111, 11335563, 11338925, 11360802, 11362930, 11365492, 11368054, 11371249, 11373863, 11376216, 11461774, 11466080, 11467200, 11483906, 11485860, 11487941, 11490141, 11492077, 11493910, 11514284, 14847331, 17389547, 17404855, 24278084, 24893120, 26611636, 26679702, 26747063, 26747064, 26751576, 29221715, 46507583, 47216705, 47365117
|
|||
| ChEBI ID |
CHEBI:3387
|
|||
| ADReCS Drug ID | BADD_D00356 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium channel unspecific (NaC) | Target Info | Modulator | [5] |
| KEGG Pathway | Dopaminergic synapse | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5339). | |||
| REF 2 | Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs. 2007;21(1):47-71. | |||
| REF 3 | Clinical pipeline report, company report or official report of Lundbeck. | |||
| REF 4 | ClinicalTrials.gov (NCT01128959) Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy. U.S. National Institutes of Health. | |||
| REF 5 | Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.